A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
Journal of Gynecologic Oncology · 2023
DOI: 10.3802/jgo.2023.34.e52 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von Ting Deng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen …. Hauptthemen laut MEDLINE: Lymph Node Excision, Ovarian Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sun Yat-sen University Clinical Research 5010 Program.
Abstract (Originalsprache)
BACKGROUND: The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC). METHODS: We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB EOC and fallopian tube carcinomas (FTC). The hypothesis is that the oncological outcomes provided by comprehensive staging surgery without lymphadenectomy are non-inferior to those of conventional completion staging surgery in early-stage EOC and FTC patients who have indications for post-operative adjuvant chemotherapy. Patients assigned to experimental group will undergo comprehensive staging surgery, but lymphadenectomy. Patients assigned to comparative group will undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy. All subjects will receive 3-6 cycles of standard adjuvant chemotherapy. Major inclusion criteria are pathologic confirmed stage IA-IIB EOC or FTC, and patients have indications for adjuvant chemotherapy either confirmed by intraoperative fast frozen section or previous pathology after an incomplete staging surgery. Major exclusion criteria are non-epithelial tumors and low-grade serous carcinoma. Patients with severe rectum involvement which lead to partial rectum resection will be excluded. The sample size is 656 subjects. Primary endpoint is disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04710797.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
- Department of Gynecology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China.
- Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Ting Deng, Kaijiang Liu, Liang Chen, Xiaojun Chen, Hua Wen Li, Hongyan Guo, Huijiao Zhang, Libing Xiang, Xin Feng, Xiaoyu Wang, Hextan Ys Ngan, Jianguo Zhao, Dongling Zou, Qing Liu, Jihong Liu
Förderung
- Sun Yat-sen University Clinical Research 5010 Program
Zitieren
APA
Deng, T., Liu, K., Chen, L., Chen, X., Li, H. W., Guo, H., Zhang, H., Xiang, L., Feng, X., Wang, X., Ngan, H. Y., Zhao, J., Zou, D., Liu, Q., & Liu, J. (2023). A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e52
Vancouver
Deng T, Liu K, Chen L, Chen X, Li HW, Guo H, et al. A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e52
BibTeX
@article{Deng2023,
author = {Deng, Ting and Liu, Kaijiang and Chen, Liang and Chen, Xiaojun and Li, Hua Wen and Guo, Hongyan and Zhang, Huijiao and Xiang, Libing and Feng, Xin and Wang, Xiaoyu and Ngan, Hextan Ys and Zhao, Jianguo and Zou, Dongling and Liu, Qing and Liu, Jihong},
title = {A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study},
journal = {Journal of Gynecologic Oncology},
year = {2023},
doi = {10.3802/jgo.2023.34.e52}
}
EUVIMED